The ExoLuminate Study

Earlier detection of pancreatic cancer in high-risk families

A new, investigational approach to detecting pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is among the most challenging cancers for clinicians to treat—and for patients to fight. Pancreatic cancer is most often diagnosed late, in Stage 3 or Stage 4 of the disease, leaving patients and clinicians with limited options.

To address this challenge, Biological Dynamics is developing an early diagnostic detection test utilizing AC Electrokinetics (ACE) to isolate exosomes (Exo) from blood.

By joining our registry study, you and your patients will be playing an important role in studying if early detection improves pancreatic cancer outcomes.

The challenge of pancreatic cancer


people diagnosed with pancreatic cancer each year


of patients are diagnosed in Stage 3 or 4


of these patients die of it each year


five-year survival rate
Source: National Cancer Institute (NCI), Surveillance, Epidemiology, and End Results (SEER)

A high-sensitivity test for a high-risk population

This revolutionary new, investigational test is powered by a patented exosome-isolation technology that yields high sensitivity results from a simple blood draw. The test is designed to be used with patients and their family members who have been identified as having elevated risk for pancreatic cancer. These high-risk factors include genetic mutations or family history, the presence of lesions in the pancreas, or adults over the age of 50 with new onset diabetes. In this study, you will be asked to provide information and blood samples. You will not receive any information from the investigational test. 



Frontiers in Bioengineering and Biotechnology
Nature’s Communication Medicine

The FDA named our technology a Breakthrough Device for Elevated Risk in PDAC
Our lab is CLIA/CAP accredited
Our lab developed test (LDT) has been listed with CMS

How can you be a part of The ExoLuminate Study?

By joining this important clinical study, you will help make a profound difference in the lives of patients with pancreatic cancer—and their families.

We are accepting high-risk patients through academic and community institutions in this study. Please contact us directly to obtain more information.

    Learn more about the ExoLuminate study

    For more information about eligibility criteria for your patients, please complete the form below.

    First Name*
    Last Name*
    Email Address*
    Phone Number
    Are you a:*
    Provider/Institution name*
    How did you hear about ExoLuminate?*
    Please enter how you heard about ExoLuminate

    Contact Us

    For Detailed Study Information
    For Media Inquiries

    About Biological Dynamics

    Biological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. The company’s proprietary ExoVerita™ platform simplifies isolation of extracellular vesicles, enabling multiomic applications. For more information, visit www.biologicaldynamics.com.